Point72 Asset Management
DMAC icon

Point72 Asset Management’s DiaMedica Therapeutics DMAC Stock Holding History

Point72 Asset Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-552,250
Closed -$5.05M – 1009
2021
Q1 		$5.05M Sell
552,250
-247,750
-31% -$2.31M 0.02% 565
2020
Q4 		$8.11M Hold
800,000
– – 0.04% 488
2020
Q3 		$3.39M Buy
+800,000
New +$4.23M 0.02% 630

Other funds holding DMAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management's DMAC Position: Q2 2021 in Review

Point72 Asset Management sold out of DiaMedica Therapeutics (DMAC) in Q2 2021, closing a stake of 552,250 shares — an estimated $5.05M sold.

Point72 Asset Management first reported a position in DMAC in Q3 2020 and held it in 3 quarters. The position peaked at $8.11M in Q4 2020. 43 funds tracked by Wall St. Rank hold DMAC as of Q2 2021.

  • Point72 Asset Management reported no remaining DiaMedica Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Point72 Asset Management sold 552,250 DiaMedica Therapeutics shares in Q2 2021, an estimated $5.05M.
  • Point72 Asset Management first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 3 quarters.
  • Point72 Asset Management's DiaMedica Therapeutics position peaked at $8.11M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2021.

Based on Point72 Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.